Malaria Vaccine 257049 for malaria

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Mar 2009: Trial registered, NCT00866619
  2. 27 Mar 2009: Trial started, NCT00866619

The trials

NCT00866619: Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa

State
Completed
Phase
Phase 3
People
15,459 taking part
Started
27 Mar 2009
Primary completion
1 Mar 2011
Arms
GSK257049 [5-17M] Group
Results
Posted on the registry
  1. 20 Mar 2009: Trial registered
  2. 27 Mar 2009: Trial started
  3. 31 Jan 2014: Trial completed
  4. 9 Oct 2019: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.